In this market, there are several products approved for multiple indications and surgical specialties, which creates greater growth potential in the market. Gelatin-based hemostats represented the smallest segment in 2018, and will continue to do so through 2025. There is little innovation in this segment and the market is moving towards alternative choices.
Hemostats, also known as anti-hemorrhagic agents, are substances that promote hemostasis, the process which causes bleeding to stop. There are a number of topical hemostats used in surgeries. Topical hemostats are suitable for minor bleeding and oozing blood from injured capillaries and venules. Physiologic hemostasis occurs with vascular constriction and is a complex process in which blood changes from a fluid to a solid state to control tissue damage and bleeding. Thrombin binds to platelets and becomes activated. They activate fibrinogen into fibrin. The fibrin monomers combine to create fibrin structures that coagulate open arteries. Platelets aggregate at the injury site (the surgical incision) to form a temporary plug.
Segments Covered in This Market
- Thrombin-Based Hemostat Market
- Oxidized Regenerated Cellulose Hemostat Market
- Gelatin-Based Hemostat Market
- Collagen-Based Hemostat Market
- Combination Hemostat Market
- Polysaccharide-Based Hemostat Market
- First Responder Hemostat Market
Report Data Types Included
- Unit Sales, Average Selling Prices, Market Value & Growth Trends
- 10 Year Scope (3 Year Historical + 7 Year Forecast Period)
- Market Drivers & Limiters for Each Segment
- Competitive Analysis with Market Shares
- Product Portfolios
- Related Press Releases from Top Competitors
Of the many companies in the United States Surgical Hemostat market, Ethicon was the leader, followed by Baxter and C. R. Bard. Ethicon held a near monopoly in the ORC-based hemostat market, with their absorbable Surgicel® family of products, which are proven bactericidal agents against a broad range of both gram-positive and gram-negative bacteria. Baxter recently acquired Recothrom®, a thrombin-based hemostat, and Preveleak®, a tissue sealant, from Mallinckrodt plc. In 2013, C. R. Bard acquired Medafor for nearly $280 million, which, at the time, made them the only company in the polysaccharide-based hemostat market and improved their overall market share in the hemostat market significantly.
About Our In-Depth MedCore Research
Our analysts meticulously research for up to 3 to 4 months to put together one suite of reports (MedSuite), which is a comprehensive analysis on a group of healthcare markets. A MedCore is one portion of that analysis that focuses on one market segment, and provides further detailed segmentation to get a much more granular set of market data.
This MedCore is also found in the full report suite titled United States Market Report Suite for Wound and Tissue Management – MedSuite